A Phase 2A Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF)


Total Award Amount

  • 20354.00
  • Direct Costs

  • 13846.00
  • Sponsor Award Id

  • 161118-STOP ALF
  • Contributor

  • Adam L. Edwards   Investigator  
  • Brendan McGuire   Principal Investigator  
  • Jenni Wise   Investigator  
  • Mohamed Shoreibah   Investigator